Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.

[1]  D. Gladman,et al.  Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study , 2004 .

[2]  D. M. van der Heijde,et al.  Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. , 2003, Arthritis and rheumatism.

[3]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[4]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[5]  J. Braun,et al.  Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. , 1998, Arthritis and rheumatism.

[6]  J. Sharp,et al.  Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.

[7]  H. Zeidler,et al.  Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis , 2004, Annals of the rheumatic diseases.

[8]  Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. , 2004, Annals of the rheumatic diseases.

[9]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[10]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[11]  M. Dougados,et al.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.

[12]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[13]  J. Braun,et al.  Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. , 2005, Rheumatology.

[14]  J. Listing,et al.  Open label trial of anakinra in active ankylosing spondylitis over 24 weeks , 2004, Annals of the rheumatic diseases.

[15]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[16]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.